A phase 2 study of weekly albumin-bound paclitaxel (Abraxane ®) given as a two-hour infusion Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms
  • Paclitaxel

abstract

  • Increasing the infusion time of albumin-bound paclitaxel from 30 min to 2 h resulted in a significant reduction in both average and grade ≥2 peripheral neuropathy without affecting survival.

publication date

  • November 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3581346

Digital Object Identifier (DOI)

  • 10.1007/s00280-011-1621-0

PubMed ID

  • 21461889

Additional Document Info

start page

  • 1331

end page

  • 7

volume

  • 68

number

  • 5